Novartis exit from antibiotics a setback for race against resistance

Katrina Megget writes about Novartis' recent announcement to drop its antibacterial and antiviral research programmes.

The author quotes views on the Novartis’ decision to exit the antibiotics market and the implications in the fight against drug-resistant infections. She also refers to the results of the Antimicrobial Resistance Benchmark published in January 2018.